{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:54:53Z","timestamp":1767664493696},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T00:00:00Z","timestamp":1194393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits. Recently, Italian investigators reported that etoposide and epirubicin combination (EE) chemotherapy was highly active against AHCC, with a response rate of 39% and a median overall survival (OS) of 10 months. We report our efficacy and safety results of EE in clinical practice.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Between December 1999 and October 2005, 35 patients with AHCC and fitting the preset eligibility criteria were treated with EE. Twenty\u2010eight patients (80%) had liver disease associated with hepatitis B virus (HBV) and 26 (74%) had a prior history of transarterial chemoembolization (TACE) using cisplatin. The EE chemotherapy consisted of epirubicin 40\u2003mg\/m<jats:sup>2<\/jats:sup> on day 1 and etoposide 120\u2003mg\/m<jats:sup>2<\/jats:sup> on days 1, 3 and 5 every 4\u2003weeks.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> A total of 102 chemotherapy cycles were administered, with a median of two cycles per patient (range one to eight cycles). Two patients had a partial response and nine had stable disease, with a tumor control rate of 32% (95% CI 17\u201348). The median progression\u2010free survival (PFS) was 2.1 months (95% CI 1.8\u20132.4) and the median OS was 6.4 months (95% CI 4.4\u20138.5). There was a tendency toward improved PFS in patients seronegative for HBsAg and peritoneal seeding (<jats:italic>P<\/jats:italic>\u2003=\u20030.06 and <jats:italic>P<\/jats:italic>\u2003=\u20030.054, respectively). Overall survival was significantly better in patients without HBsAg and Cancer Liver Italian Program (CLIP) score 0\u20131 (<jats:italic>P<\/jats:italic>\u2003=\u20030.024 and <jats:italic>P<\/jats:italic>\u2003=\u20030.033, respectively). The main toxicities were hematological events, including grade 3\/4 neutropenia in 29% and febrile neutropenia in 11% of patients.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Treatment with EE showed minimal antitumor activity with acceptable toxicity in HBV\u2010associated AHCC, especially in patients pretreated with TACE.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2007.05213.x","type":"journal-article","created":{"date-parts":[[2007,11,8]],"date-time":"2007-11-08T03:31:37Z","timestamp":1194492697000},"page":"811-816","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis"],"prefix":"10.1111","volume":"23","author":[{"given":"Jae\u2010Lyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min\u2010Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heung M","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae\u2010Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun J","family":"Sym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min K","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang M","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon\u2010Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<912::AID-CNCR23>3.0.CO;2-T"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01508-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00286.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008285123736"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1309\/AC1M-4TY4-U0TN-EN7T"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.9.700"},{"key":"e_1_2_6_11_2","first-page":"1960","article-title":"Therapeutic results using VP 16\u2010213 alone or in combination with 5\u2010fluorouracil in liver cancer (hepatoma)","volume":"107","author":"Cavalli F","year":"1977","journal-title":"Schweiz Med. Wochenschr."},{"key":"e_1_2_6_12_2","first-page":"120","article-title":"A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group","volume":"19","author":"Yoshino M","year":"1989","journal-title":"Jpn. J. Clin. Oncol."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<872::AID-CNCR10>3.0.CO;2-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345050-00011"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.11.1535"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685565"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00163-9"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280322"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0243"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11528"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270413"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.9603"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00364.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21572"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.12.755"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02557522"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2007.05213.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2007.05213.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:32:19Z","timestamp":1696897939000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2007.05213.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,7]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1440-1746.2007.05213.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2007.05213.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,7]]},"assertion":[{"value":"2007-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}